Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Titel:
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Auteur:
Rochlitz, C. Ruhstaller, T. Lerch, S. Spirig, C. Huober, J. Suter, T. Bühlmann, M. Fehr, M. Schönenberger, A. von Moos, R. Winterhalder, R. Rauch, D. Müller, A. Mannhart-Harms, M. Herrmann, R. Cliffe, B. Mayer, M. Zaman, K.